October 24, 2015 –  The Amrican Food and Drug Administration approved Trabectedin (Yondelis) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. The approval of trabectedin is based on improvement in progression-free survival (PFS) in a multicenter, …

Trabectedin (Yondelis) approved by the FDA for unresectable or metastatic liposarcoma or leiomyosarcoma Read more »